MRC Technology and Biolex Therapeutics Successfully Complete Collaboration to Humanize a Novel Antibody Targeting CD20
7/14/2008 8:53:36 AM
LONDON and PITTSBORO, NC--(Marketwire - July 14, 2008) - MRC Technology (MRCT) (London, UK) and Biolex Therapeutics, Inc. (Pittsboro, North Carolina, USA) announced today that MRCT had successfully completed the humanization of a novel antibody targeting CD20, indicated in non-Hodgkin's lymphoma and rheumatoid arthritis. Biolex is applying its proprietary glycosylation optimization technology to the antibody, BLX-301, to enhance efficacy and potency of the product candidate and potentially reduce certain side effects.
comments powered by